The Liver Meeting 2020-2020 NAFLD Debrief

Video Transcription

Video Summary

The 2020 NAFLD debrief from the ASLD meeting highlighted several key treatment trials for NASH. Professor Sven Franky discussed the promising results of the pan-PPAR agonist Lena Fibrenor in patients with non-cerotic NASH, showing significant improvements in NASH activity scores and histological endpoints. Another study by Professor Newsome presented subcutaneous semaglutide as a potential treatment for NASH, demonstrating resolution of steatohepatitis with no worsening in fibrosis. Dr. Sanyal shared data on the FXR agonist Propefexor, showing improvements in MRI-PDFF, though no significant histological benefits were observed. Exciting findings were also reported on FGF19 analog Aldofermin, showing impressive effects on liver fat reduction and potential histological benefits. Further studies on fatty acid synthase inhibitors and other novel mechanisms for NASH treatment were presented. Additionally, research on metabolic-associated fatty liver disease and non-invasive assessments using liver multi-scan were discussed, providing valuable insights for future clinical trials and patient care.

Keywords

NAFLD

ASLD meeting

NASH treatment trials

pan-PPAR agonist

semaglutide

FXR agonist